BR112021023216A2 - Fused heterocyclic derivatives as antiviral agents - Google Patents
Fused heterocyclic derivatives as antiviral agentsInfo
- Publication number
- BR112021023216A2 BR112021023216A2 BR112021023216A BR112021023216A BR112021023216A2 BR 112021023216 A2 BR112021023216 A2 BR 112021023216A2 BR 112021023216 A BR112021023216 A BR 112021023216A BR 112021023216 A BR112021023216 A BR 112021023216A BR 112021023216 A2 BR112021023216 A2 BR 112021023216A2
- Authority
- BR
- Brazil
- Prior art keywords
- fused heterocyclic
- antiviral agents
- heterocyclic derivatives
- compounds
- derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
derivados heterocíclicos fundidos como agentes antivirais. a presente invenção refere-se a compostos de derivados heterocíclicos fundidos, composições farmacêuticas compreendendo estes compostos, processos químicos para preparar estes compostos e seu uso no tratamento de doenças associadas à infecção pelo hbv.fused heterocyclic derivatives as antiviral agents. The present invention relates to fused heterocyclic derivative compounds, pharmaceutical compositions comprising these compounds, chemical processes for preparing these compounds, and their use in the treatment of diseases associated with hbv infection.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962853554P | 2019-05-28 | 2019-05-28 | |
EP19176954 | 2019-05-28 | ||
PCT/US2020/034654 WO2020243142A1 (en) | 2019-05-28 | 2020-05-27 | Fused heterocyclic derivatives as antiviral agents |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112021023216A2 true BR112021023216A2 (en) | 2022-01-04 |
Family
ID=71523196
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112021023216A BR112021023216A2 (en) | 2019-05-28 | 2020-05-27 | Fused heterocyclic derivatives as antiviral agents |
Country Status (10)
Country | Link |
---|---|
US (1) | US20220323455A1 (en) |
EP (1) | EP3976616A1 (en) |
JP (1) | JP2022535208A (en) |
KR (1) | KR20220012321A (en) |
CN (1) | CN113939512A (en) |
AU (1) | AU2020285719A1 (en) |
BR (1) | BR112021023216A2 (en) |
CA (1) | CA3138163A1 (en) |
MX (1) | MX2021014576A (en) |
WO (1) | WO2020243142A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024114709A1 (en) * | 2022-12-01 | 2024-06-06 | Janssen Sciences Ireland Unlimited Company | A crystal form of a fused heterocycle derivative compound |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2993174A1 (en) * | 2014-09-08 | 2016-03-09 | Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt GmbH | Pyrazolopyridine derivatives and their use in therapy |
US9550779B2 (en) * | 2014-12-30 | 2017-01-24 | Novira Therapeutics, Inc. | Derivatives and methods of treating hepatitis B infections |
US10975077B2 (en) * | 2016-06-29 | 2021-04-13 | Novira Therapeutics, Inc. | Diazepinone derivatives and their use in the treatment of hepatitis B infections |
CN109843892B (en) * | 2016-06-29 | 2022-01-25 | 诺维拉治疗公司 | Oxadiazepinone derivatives and their use in the treatment of hepatitis B infections |
-
2020
- 2020-05-27 BR BR112021023216A patent/BR112021023216A2/en not_active Application Discontinuation
- 2020-05-27 CA CA3138163A patent/CA3138163A1/en active Pending
- 2020-05-27 KR KR1020217042057A patent/KR20220012321A/en unknown
- 2020-05-27 EP EP20737307.7A patent/EP3976616A1/en not_active Withdrawn
- 2020-05-27 JP JP2021570292A patent/JP2022535208A/en active Pending
- 2020-05-27 AU AU2020285719A patent/AU2020285719A1/en not_active Abandoned
- 2020-05-27 WO PCT/US2020/034654 patent/WO2020243142A1/en unknown
- 2020-05-27 US US17/595,796 patent/US20220323455A1/en active Pending
- 2020-05-27 MX MX2021014576A patent/MX2021014576A/en unknown
- 2020-05-27 CN CN202080039761.1A patent/CN113939512A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
KR20220012321A (en) | 2022-02-03 |
JP2022535208A (en) | 2022-08-05 |
CN113939512A (en) | 2022-01-14 |
MX2021014576A (en) | 2022-01-11 |
WO2020243142A1 (en) | 2020-12-03 |
EP3976616A1 (en) | 2022-04-06 |
AU2020285719A1 (en) | 2022-02-03 |
CA3138163A1 (en) | 2020-12-03 |
US20220323455A1 (en) | 2022-10-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112021022889A2 (en) | Fused heterocyclic derivatives | |
DOP2018000226A (en) | NEW DERIVATIVES OF PIRAZOLOPIRIMIDINA | |
BR112017011941A2 (en) | Substituted 5-amino-6h-thiazol [4,5-d] pyrimidine-2,7-dione compounds for the treatment and prophylaxis of viral infection | |
CY1120673T1 (en) | 2- (MORPHOLIN-4-YL) -1,7-Naphthyridines | |
BR112018008880A2 (en) | As a TLR7 agonist of the 7- (thiazol-5-yl) pyrrolopyrimidine compound | |
BR112018009281A8 (en) | compositions for treating spinal muscular atrophy | |
CO2020001244A2 (en) | Quinoline derivatives to treat helminth infections | |
BR112017015242A2 (en) | pyrazine compounds for the treatment of infectious diseases | |
UY37645A (en) | INDOLINA DERIVATIVES REPLACED AS INHIBITORS OF THE DENGUE VIRIC REPLICATION | |
CU20150096A7 (en) | AMIDA COMPOUNDS AND PHARMACEUTICAL COMPOSITION FOR HIV TREATMENT | |
BR112016017261A8 (en) | compound, pharmaceutical composition, use of a compound and process for the manufacture of a compound | |
UY32462A (en) | NEW BIFENYLL DERIVATIVES FOR HEPATITIS C 644 VIRUS INFECTION TREATMENT | |
BR112017023263A2 (en) | rsv antiviral compounds of pyrazole and triazolopyrimidine | |
UY37741A (en) | INDOLINA DERIVATIVES REPLACED AS INHIBITORS OF THE DENGUE VIRUS REPLICATION | |
UY37646A (en) | INDOLINA DERIVATIVES REPLACED AS INHIBITORS OF THE DENGUE VIRIC REPLICATION | |
DOP2015000169A (en) | TETRACYCLIC COMPOUNDS REPLACED WITH HETEROCICLE AND USES OF THE SAME FOR THE TREATMENT OF VIVIC DISEASES | |
CO2021011295A2 (en) | Ring fused pyrimidone derivatives for use in treating HBV infection or HBV-induced diseases | |
UY37496A (en) | N- [5- (AMINOSULFONYL) -4-METHYL-1,3-TIAZOL-2-IL] -N-METHYL-2- [4- (2-PYRIDINYL) -PHENYL] -ACETAMIDE FREE BASE HEMIHYDRATE MANUFACTURING METHODS AND USES OF THE SAME | |
CO2020013876A2 (en) | New quinoline derivatives | |
UY38228A (en) | TRIAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER | |
UY37972A (en) | MACROCYCLIC INDOL DERIVATIVES SUBSTITUTED WITH CHLORINE | |
BR112017001160A2 (en) | [1,2,4] triazole [4,3-b] pyridazine for use in the treatment of proliferative diseases | |
BR112021023216A2 (en) | Fused heterocyclic derivatives as antiviral agents | |
CU20200100A7 (en) | HYDROTIENOPYRIDINE 3-CYANE N-SUBSTITUTE COMPOUNDS USEFUL TO PREVENT AND TREAT VIRAL INFECTIONS, ESPECIALLY DENGUE, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | |
ECSP21092791A (en) | CONDENSED HETEROCYCLIC DERIVATIVES |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |